Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
In the latest session, Mirum Pharmaceuticals Inc (NASDAQ: MIRM) closed at $73.87 down -2.20% from its previous closing price of $75.53. In other words, the price has decreased by -$2.20 from its previous closing price. On the day, 1.08 million shares were traded. MIRM stock price reached its highest trading level at $75.74 during the session, while it also had its lowest trading level at $73.12.
Ratios:
For a deeper understanding of Mirum Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.19 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 430.02. For the most recent quarter (mrq), Quick Ratio is recorded 2.97 and its Current Ratio is at 3.13. In the meantime, Its Debt-to-Equity ratio is 1.25 whereas as Long-Term Debt/Eq ratio is at 1.24.
On April 17, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $48.Stifel initiated its Buy rating on April 17, 2024, with a $48 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 11 ’25 when Peetz Christopher sold 40,000 shares for $62.00 per share. The transaction valued at 2,480,000 led to the insider holds 138,641 shares of the business.
CHRISTOPHER PEETZ bought 40,000 shares of MIRM for $2,480,000 on Aug 11 ’25. On Aug 07 ’25, another insider, Howe Jolanda, who serves as the SVP, GLOBAL CONTROLLER of the company, sold 10,000 shares for $58.00 each. As a result, the insider received 580,000 and left with 2,426 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MIRM now has a Market Capitalization of 3711051776 and an Enterprise Value of 3725401088. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.65 while its Price-to-Book (P/B) ratio in mrq is 14.49. Its current Enterprise Value per Revenue stands at 8.681 whereas that against EBITDA is -113.375.
Stock Price History:
The Beta on a monthly basis for MIRM is 0.95, which has changed by 0.7881869 over the last 52 weeks, in comparison to a change of 0.16844666 over the same period for the S&P500. Over the past 52 weeks, MIRM has reached a high of $75.62, while it has fallen to a 52-week low of $36.86. The 50-Day Moving Average of the stock is 29.22%, while the 200-Day Moving Average is calculated to be 53.75%.
Shares Statistics:
For the past three months, MIRM has traded an average of 581.07K shares per day and 910530 over the past ten days. A total of 50.06M shares are outstanding, with a floating share count of 40.53M. Insiders hold about 19.31% of the company’s shares, while institutions hold 94.46% stake in the company. Shares short for MIRM as of 1755216000 were 6926980 with a Short Ratio of 11.92, compared to 1752537600 on 6580855. Therefore, it implies a Short% of Shares Outstanding of 6926980 and a Short% of Float of 13.79.
Earnings Estimates
The performance of Mirum Pharmaceuticals Inc (MIRM) in the stock market is under the watchful eye of 8.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.14, with high estimates of $0.07 and low estimates of -$0.25.
Analysts are recommending an EPS of between -$0.34 and -$1.0 for the fiscal current year, implying an average EPS of -$0.7. EPS for the following year is $0.06, with 9.0 analysts recommending between $1.28 and -$0.74.
Revenue Estimates
A total of 8 analysts believe the company’s revenue will be $129.21M this quarter.It ranges from a high estimate of $134.16M to a low estimate of $122.3M. As of the current estimate, Mirum Pharmaceuticals Inc’s year-ago sales were $90.38MFor the next quarter, 8 analysts are estimating revenue of $135.87M. There is a high estimate of $140.79M for the next quarter, whereas the lowest estimate is $129.7M.
A total of 9 analysts have provided revenue estimates for MIRM’s current fiscal year. The highest revenue estimate was $513.83M, while the lowest revenue estimate was $491.6M, resulting in an average revenue estimate of $504.24M. In the same quarter a year ago, actual revenue was $336.89MBased on 10 analysts’ estimates, the company’s revenue will be $600.04M in the next fiscal year. The high estimate is $650.83M and the low estimate is $558.04M.
